TD Cowen analyst Tara Bancroft downgraded Fusion Pharmaceuticals (FUSN) to Hold from Buy following the proposed acquisition by AstraZeneca (AZN). The firm believes another party is unlikely to counter and the transaction should close in Q2, adding that the Phase 2 TATCIST data at AACR “suggest strong potential in post-Pluvicto patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FUSN:
- Fusion announces presentation of data from Phase 2 TATCIST clinical trial
- What the Fusion Pharmaceuticals (NASDAQ:FUSN) Acquisition Means for Investors
- Largest borrow rate increases among liquid names
- Fusion Pharmaceuticals Accelerates Oncology Pipeline
- Fusion Pharmaceuticals reports Q4 EPS (39c), consensus (34c)